INDICATION AND LIMITATIONS OF USE

YORVIPATH (palopegteriparatide) is indicated for the treatment of hypoparathyroidism in adults.

YORVIPATH was not studied for acute post-surgical hypoparathyroidism. YORVIPATH’s titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of ≥ 7.8 mg/dL using calcium and active vitamin D treatment.

This site is intended for US healthcare professionals only.

For US Patients Prescribing Information Indication/Limitations of Use

stay-informed

The information contained in this website is intended for US healthcare professionals only.

Please confirm that you are a US HCP.

NO, I am not a US HCP

You are about to leave the YorvipathHCP.com website by opening a new webpage.

The site you are linking to is not controlled or endorsed by Ascendis Pharma and we are not responsible for the content presented on that site.

Thank you for visiting YorvipathHCP.com.

Continue
Webinar Icon

UPCOMING WEBINARS

Learn about hypoparathyroidism and managing this disease from your peers in endocrinology.

Register now